LIXILAN JP-O2: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Study Details
Study Description
Brief Summary
Primary Objective:
To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 Diabetes.
Secondary Objective:
To compare the overall efficacy and safety of LixiLan to insulin glargine (with or without OADs) over a 26 Week treatment period in patients with type 2 Diabetes.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
The maximum study duration per patient will be approximately 29 weeks: an up to 2-week screening period, a 26-week randomized open-label treatment period and a 3-day post-treatment safety follow up period.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: LixiLan LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period. |
Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)
Pharmaceutical form: solution
Route of administration: subcutaneous
Other Names:
Drug: Oral anti-diabetic drugs
Pharmaceutical form: tablet
Route of administration: oral
|
Active Comparator: insulin glargine Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period. |
Drug: Insulin glargine (HOE901)
Pharmaceutical form: solution
Route of administration: subcutaneous
Drug: Oral anti-diabetic drugs
Pharmaceutical form: tablet
Route of administration: oral
|
Outcome Measures
Primary Outcome Measures
- Change from baseline in HbA1c [Baseline, 26 weeks]
Secondary Outcome Measures
- Percentage of patients reaching HbA1c <7% or ≤6.5% [26 weeks]
- Change from baseline in 2-hour postprandial glucose (PPG) during standardized meal test [Baseline, 26 weeks]
- Change from baseline in 7 point self monitored plasma glucose (SMPG) profiles during standardized meal test [Baseline, 26 weeks]
- Change from baseline in body weight [Baseline, 26 weeks]
- Percentage of patients reaching HbA1c <7% with no body weight gain and with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia [26 weeks]
- Percentage of patients reaching HbA1c <7% at Week 26 with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia [26 weeks]
- Percentage of patients requiring a rescue therapy [26 weeks]
- Number of adverse events [26 weeks]
- Number of hypoglycemic events [26 weeks]
- Measurement of anti-lixisenatide antibodies from baseline [Baseline, 26 weeks]
- Measurement of anti-insulin antibodies from baseline [Baseline, 26 weeks]
Eligibility Criteria
Criteria
Inclusion criteria :
-
Patient with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit, receiving 1 or 2 OADs that can be Biguanide,Thiazolidinedione (TZD), -Alpha-glucosidase-inhibitor (alpha-GI),Sodium glucose co-transporter 2 (SGLT2) inhibitor,Sulfonylurea (SU),Rapid-acting insulin secretagogue (Glinide),diphenyl-peptidase -4 inhibitor (DPP-4 inhibitor).
-
Signed written informed consent.
Exclusion criteria:
-
At the screening visit: Age <20 years.
-
At the screening visit: HbA1c <7.5% or >9.5%.
-
At the screening visit: fasting plasma glucose (FPG) >180 mg/dL (10.0 mmol/L).
-
Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.
-
Use of oral or injectable glucose-lowering agents other than those stated during the inclusion criteria in the 3 months before the screening visit.
-
Previous treatment with insulin (except for short-term treatment due to intercurrent illness including gestational diabetes at the discretion of the trial physician).
-
Laboratory findings at the time of screening:
-
Amylase and/or lipase: >3 times the upper limit of the normal (ULN) laboratory range,
-
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST): >3 ULN,
-
Calcitonin ≥20 pg/mL (5.9 pmol/L),
-
Positive serum pregnancy test in female of childbearing potential.
-
Contraindication to use of lixisenatide according to the local labeling. History of hypersensitivity to any Glucagon-Like Peptide-1 Receptor Agonists or to metacresol.
-
Contraindication to use of insulin glargine according to local labeling. History of hypersensitivity to insulin glargine or to any of the excipients.
-
Patient who has a severe renal function impairment with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 or end-stage renal disease for patient not treated with metformin.
-
Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (eg, multiple endocrine neoplasia syndromes).
-
History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy, stomach/gastric surgery.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Investigational Site Number 392002 | Adachi-Ku | Japan | ||
2 | Investigational Site Number 392132 | Annaka-Shi | Japan | ||
3 | Investigational Site Number 392009 | Arakawa-Ku | Japan | ||
4 | Investigational Site Number 392025 | Atsugi-Shi | Japan | ||
5 | Investigational Site Number 392024 | Chiba-Shi | Japan | ||
6 | Investigational Site Number 392151 | Chiba-Shi | Japan | ||
7 | Investigational Site Number 392011 | Chigasaki-Shi | Japan | ||
8 | Investigational Site Number 392013 | Chiyoda-Ku | Japan | ||
9 | Investigational Site Number 392052 | Chiyoda-Ku | Japan | ||
10 | Investigational Site Number 392003 | Chuo-Ku | Japan | ||
11 | Investigational Site Number 392017 | Chuo-Ku | Japan | ||
12 | Investigational Site Number 392055 | Chuo-Ku | Japan | ||
13 | Investigational Site Number 392155 | Chuo-Ku | Japan | ||
14 | Investigational Site Number 392008 | Fujimi-Shi | Japan | ||
15 | Investigational Site Number 392143 | Fujisawa-Shi | Japan | ||
16 | Investigational Site Number 392054 | Fukuoka-Shi | Japan | ||
17 | Investigational Site Number 392094 | Fukuoka-Shi | Japan | ||
18 | Investigational Site Number 392147 | Fukuoka-Shi | Japan | ||
19 | Investigational Site Number 392100 | Gifu-Shi | Japan | ||
20 | Investigational Site Number 392059 | Hachioji-Shi | Japan | ||
21 | Investigational Site Number 392083 | Hakodate-Shi | Japan | ||
22 | Investigational Site Number 392048 | Hamamatsu-Shi | Japan | ||
23 | Investigational Site Number 392102 | Hamamatsu-Shi | Japan | ||
24 | Investigational Site Number 392079 | Hiki-Gun | Japan | ||
25 | Investigational Site Number 392112 | Hirosaki-Shi | Japan | ||
26 | Investigational Site Number 392109 | Hofu-Shi | Japan | ||
27 | Investigational Site Number 392057 | Iruma-Shi | Japan | ||
28 | Investigational Site Number 392022 | Ise-Shi | Japan | ||
29 | Investigational Site Number 392020 | Izumisano-Shi | Japan | ||
30 | Investigational Site Number 392139 | Kagoshima-Shi | Japan | ||
31 | Investigational Site Number 392136 | Kamogawa-Shi | Japan | ||
32 | Investigational Site Number 392066 | Kashiwa-Shi | Japan | ||
33 | Investigational Site Number 392045 | Kashiwara-Shi | Japan | ||
34 | Investigational Site Number 392006 | Kasugai-Shi | Japan | ||
35 | Investigational Site Number 392053 | Kawagoe-Shi | Japan | ||
36 | Investigational Site Number 392065 | Kawagoe-Shi | Japan | ||
37 | Investigational Site Number 392007 | Kawaguchi-Shi | Japan | ||
38 | Investigational Site Number 392062 | Kawaguchi-Shi | Japan | ||
39 | Investigational Site Number 392077 | Kawasaki-Shi | Japan | ||
40 | Investigational Site Number 392082 | Kawasaki-Shi | Japan | ||
41 | Investigational Site Number 392091 | Kawasaki-Shi | Japan | ||
42 | Investigational Site Number 392142 | Kawasaki-Shi | Japan | ||
43 | Investigational Site Number 392133 | Kitaazumi-Gun | Japan | ||
44 | Investigational Site Number 392129 | Kitakyushu-Shi | Japan | ||
45 | Investigational Site Number 392041 | Kitakyusyu-Shi | Japan | ||
46 | Investigational Site Number 392068 | Kitakyusyu-Shi | Japan | ||
47 | Investigational Site Number 392114 | Kitamoto-Shi | Japan | ||
48 | Investigational Site Number 392086 | Kobe-Shi | Japan | ||
49 | Investigational Site Number 392044 | Koga-Shi | Japan | ||
50 | Investigational Site Number 392119 | Kokubunji-Shi | Japan | ||
51 | Investigational Site Number 392001 | Koriyama-Shi | Japan | ||
52 | Investigational Site Number 392028 | Kumamoto-Shi | Japan | ||
53 | Investigational Site Number 392092 | Kumamoto-Shi | Japan | ||
54 | Investigational Site Number 392108 | Kumamoto-Shi | Japan | ||
55 | Investigational Site Number 392075 | Kure-Shi | Japan | ||
56 | Investigational Site Number 392032 | Kurume-Shi | Japan | ||
57 | Investigational Site Number 392118 | Kushiro-Shi | Japan | ||
58 | Investigational Site Number 392107 | Kyoto-Shi | Japan | ||
59 | Investigational Site Number 392088 | Maebashi-Shi | Japan | ||
60 | Investigational Site Number 392113 | Matsumoto-Shi | Japan | ||
61 | Investigational Site Number 392122 | Minato-Ku | Japan | ||
62 | Investigational Site Number 392076 | Misato-Shi | Japan | ||
63 | Investigational Site Number 392042 | Mito-Shi | Japan | ||
64 | Investigational Site Number 392078 | Mito-Shi | Japan | ||
65 | Investigational Site Number 392148 | Nagano-Shi | Japan | ||
66 | Investigational Site Number 392026 | Nagoya-Shi | Japan | ||
67 | Investigational Site Number 392101 | Nagoya-Shi | Japan | ||
68 | Investigational Site Number 392128 | Nagoya-Shi | Japan | ||
69 | Investigational Site Number 392131 | Nagoya-Shi | Japan | ||
70 | Investigational Site Number 392134 | Nagoya-Shi | Japan | ||
71 | Investigational Site Number 392154 | Naka-Shi | Japan | ||
72 | Investigational Site Number 392127 | Niigata-Shi | Japan | ||
73 | Investigational Site Number 392050 | Niihama-Shi | Japan | ||
74 | Investigational Site Number 392115 | Ogawa-Machi, Hikigun | Japan | ||
75 | Investigational Site Number 392071 | Okayama-Shi | Japan | ||
76 | Investigational Site Number 392095 | Onga-Gun | Japan | ||
77 | Investigational Site Number 392117 | Osaka-Shi | Japan | ||
78 | Investigational Site Number 392144 | Osaka-Shi | Japan | ||
79 | Investigational Site Number 392040 | Oyama-Shi | Japan | ||
80 | Investigational Site Number 392084 | Saga-Shi | Japan | ||
81 | Investigational Site Number 392069 | Saijo-Shi | Japan | ||
82 | Investigational Site Number 392030 | Saitama-Shi | Japan | ||
83 | Investigational Site Number 392074 | Sanda-Shi | Japan | ||
84 | Investigational Site Number 392047 | Sapporo-Shi | Japan | ||
85 | Investigational Site Number 392089 | Sapporo-Shi | Japan | ||
86 | Investigational Site Number 392150 | Sapporo-Shi | Japan | ||
87 | Investigational Site Number 392097 | Sasebo-Shi | Japan | ||
88 | Investigational Site Number 392004 | Sendai-Shi | Japan | ||
89 | Investigational Site Number 392103 | Sendai-Shi | Japan | ||
90 | Investigational Site Number 392070 | Shimonoseki-Shi | Japan | ||
91 | Investigational Site Number 392034 | Shimotsuke-Shi | Japan | ||
92 | Investigational Site Number 392110 | Shinagawa-Ku | Japan | ||
93 | Investigational Site Number 392021 | Shinjuku-Ku | Japan | ||
94 | Investigational Site Number 392098 | Shinjuku-Ku | Japan | ||
95 | Investigational Site Number 392037 | Shizuoka-Shi | Japan | ||
96 | Investigational Site Number 392081 | Shizuoka-Shi | Japan | ||
97 | Investigational Site Number 392019 | Shobara-Shi | Japan | ||
98 | Investigational Site Number 392018 | Shunan-Shi | Japan | ||
99 | Investigational Site Number 392027 | Suita-Shi | Japan | ||
100 | Investigational Site Number 392056 | Taito-Ku | Japan | ||
101 | Investigational Site Number 392146 | Takamatsu-Shi | Japan | ||
102 | Investigational Site Number 392051 | Takatsuki-Shi | Japan | ||
103 | Investigational Site Number 392061 | Tokorozawa-Shi | Japan | ||
104 | Investigational Site Number 392111 | Tomakomai-Shi | Japan | ||
105 | Investigational Site Number 392029 | Toyonaka-Shi | Japan | ||
106 | Investigational Site Number 392073 | Tsu-Shi | Japan | ||
107 | Investigational Site Number 392063 | Ube-Shi | Japan | ||
108 | Investigational Site Number 392093 | Ube-Shi | Japan | ||
109 | Investigational Site Number 392039 | Yamato-Shi | Japan | ||
110 | Investigational Site Number 392067 | Yatsushiro-Shi | Japan | ||
111 | Investigational Site Number 392012 | Yokohama-Shi | Japan | ||
112 | Investigational Site Number 392126 | Yokohama-Shi | Japan | ||
113 | Investigational Site Number 392035 | Zentsuji-Shi | Japan |
Sponsors and Collaborators
- Sanofi
Investigators
- Study Director: Clinical Sciences & Operations, Sanofi
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EFC14114
- U1111-1176-8450